Back to Journals » Cancer Management and Research » Volume 12

Functions and Clinical Significance of UPF3a Expression in Human Colorectal Cancer

Authors Bao X, Huang Y, Xu W, Xiong G

Received 2 January 2020

Accepted for publication 19 April 2020

Published 8 June 2020 Volume 2020:12 Pages 4271—4281

DOI https://doi.org/10.2147/CMAR.S244486

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Sanjeev Srivastava


Xinmin Bao,1,* Yuji Huang,2,3,* Weimin Xu,2,3 Gongyou Xiong1

1No.1 People´s Hospital, Jiujiang City, Jiangxi Province, People’s Republic of China; 2Department of Colorectal Surgery, Xin‐Hua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China; 3Shanghai Colorectal Cancer Research Center, Shanghai, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Yuji Huang; Gongyou Xiong Email yujihuangrain@163.com; 523806759@qq.com

Background: Nonsense-mediated mRNA decay (NMD) can degrade mRNAs with a premature termination codon (PTC), and undegraded mRNAs with PTC mutations can induce a genetic compensation response (GCR) by upregulating its compensatory genes. UPF3a refers to up-frame shift 3A (UPF3a) participating in NMD pathway and GCR. It inhibits the NMD pathway while it stimulates GCR. Notably, the role of UPF3a in cancer remains unclear.
Purpose: The identification and discovery of prognostic markers for colorectal cancer (CRC) are of great clinical significance. The aim of this study was to investigate clinical significance of UPF3a expression in CRC.
Materials and Methods: UPF3a expression was examined in fresh CRC tissues and pared distant metastatic tissues using quantitative real-time PCR, Western blotting and immunohistochemistry staining. Tissue microarray immunohistochemical staining was used to study the relationship of UPF3a with clinicopathological features in 158 CRC patient samples collected from January 2008 to December 2012, and prognosis of CRC was analyzed.
Results: The expression of UPF3a was higher in metastatic tissues than that in primary sites. Moreover, high expression of UPF3a was significantly associated with TNM stage (p=0.009), liver metastasis and recurrence (p< 0.001) in CRC patients. The Cancer Genome Atlas (TCGA) database showed the same trend. In CRC cells, knockdown of UPF3a led to a decline in the migration potential. Kaplan–Meier survival analysis revealed that high UPF3a expression, TNM stage were significantly associated (all P< 0.01) with poor prognosis for patients. Furthermore, univariate and multivariate Cox analysis revealed that high UPF3a expression was independent risk factor for both overall survival and disease-free survival of CRC patients (all P< 0.01).
Conclusion: Results showed that high levels of UPF3a could lead to aggressiveness and poor CRC prognosis. Targeted UPF3a can act as a novel and effective gene therapy for CRC patients to make a better prognosis.

Keywords: UPF3a, colorectal cancer, TCGA, NMD pathway, genetic compensation response, metastasis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]